iAnthus Capital Stock Forecast, Price & News

iAnthus Capital (OTCMKTS:ITHUF) Frequently Asked Questions

What stocks does MarketBeat like better than iAnthus Capital?

Wall Street analysts have given iAnthus Capital a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but iAnthus Capital wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting iAnthus Capital?

iAnthus Capital saw a decrease in short interest in the month of September. As of September 30th, there was short interest totaling 3,100 shares, a decrease of 24.4% from the September 15th total of 4,100 shares. Based on an average daily volume of 520,900 shares, the days-to-cover ratio is presently 0.0 days.
View iAnthus Capital's Short Interest.

When is iAnthus Capital's next earnings date?

iAnthus Capital is scheduled to release its next quarterly earnings announcement on Thursday, November 25th 2021.
View our earnings forecast for iAnthus Capital.

How has iAnthus Capital's stock been impacted by Coronavirus (COVID-19)?

iAnthus Capital's stock was trading at $0.5282 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ITHUF shares have decreased by 64.9% and is now trading at $0.1853.
View which stocks have been most impacted by COVID-19.

Who are iAnthus Capital's key executives?

iAnthus Capital's management team includes the following people:

• Mr. Randy Maslow, Co-Founder, Pres, MD, Interim CEO & Director (Age 66, Pay $675k)
• Mr. Julius John Kalcevich, CFO & Corp. Sec. (Age 46, Pay $675k)
• Mr. Robert R. Galvin, Sr. VP, Chief Admin. Officer & Interim COO (Age 60, Pay $7.15M)
• Ms. Megan W. Kulick CFA, VP of Investor Relations
• Mr. Andrew R. Ryan Esq., Gen. Counsel
• Mr. Ethan F. Anderson, Sr. VP of Marketing (Age 49)
• Dr. Richard J. Boxer, Chief Medical Officer
• Mr. John Traylor Henderson, Sr. VP of Eastern Operations
• Mr. Michael R. Woolston, Sr. VP of Manufacturing, Supply Chain & Quality

Who are some of iAnthus Capital's key competitors?

Some companies that are related to iAnthus Capital include Abacus Health Products (ABAHF), Acreage (ACRGF), Alliance Growers (ACG), Althea Group (AGH), Applied Biosciences (APPB), AusCann Group (AC8), Ayr Strategies (AYRSF), Bio-Rad Laboratories (BIO), Blueberries Medical (BBM), Can B (CANB), Cannara Biotech (LOVE), CannPal Animal Therapeutics (CP1), Cansortium (CNTMF), Chalice Brands (GLDFF) and Charlotte's Web (CWBHF).
View all of ITHUF's competitors.

What is iAnthus Capital's stock symbol?

iAnthus Capital trades on the OTCMKTS under the ticker symbol "ITHUF."

How do I buy shares of iAnthus Capital?

Shares of ITHUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iAnthus Capital's stock price today?

One share of ITHUF stock can currently be purchased for approximately $0.19.

How many employees does iAnthus Capital have?

iAnthus Capital employs 930 workers across the globe.

What is iAnthus Capital's official website?

The official website for iAnthus Capital is www.ianthuscapital.com.

Where are iAnthus Capital's headquarters?

iAnthus Capital is headquartered at 505 Fifth Avenue, New York, NY 10017.